CoreRx, Inc. Unveils SuiteView - Plans for Novel View into GMP Manufacturing Suites
CoreRx, Inc., a Tampa-based pharmaceutical development company, which has already begun a major expansion of its new headquarters at 14205 Myerlake Circle, today announces the addition of SuiteView to its service offerings.
CoreRx, Inc. wins The CMO Leadership Award
CoreRx Inc., announced today that it won the 2011 CMO Leadership Award recognized as a category leader for Reliability, Regulatory and Productivity. CoreRx scored this in three categories: Solids, Semi-Solids and Liquids.
CoreRx Continues to Increase Staff - Adds BD Director
CoreRx has appointed William Beck as Director, Business Development, covering the Northeast. Mr. Beck will be responsible for all business development activities in support of the company’s strategic growth and development plans for this region.
CoreRx Continues to Expand - Adds Additional Capabilities
CoreRx, a leader in early drug contract development, has expanded manufacturing capabilities to include the OYSTAR Manesty FLEXITAB, A fully automated, single station tablet press with a multi-layer tablet function, giving it the unique capacity to produce three-layer tablets using a minimal amount of material. Its variable punch displacement and dwell time can be set to simulate compression on any rotary press using compression forces up to100kN.
CoreRx™ has Four Employees Named as Assistant Professors at USF’s School of Pharmacy
Todd Daviau, Matt Greene, Adam Lambert and Brian McMillan given four year appointments to begin teaching this inaugural school year
(Tampa, FL; 15 August 2011) – CoreRx, a leader in early drug development services, today announced the appointments of Todd Daviau, Matt Greene, Adam Lambert and Brian McMillan to the Faculty of the School of Pharmacy at the University of South Florida, as Assistant Professors.
CoreRx Continues to Expand – Increases Development/Manufacturing Capabilities
CoreRx, fast becoming a world-recognized leader in early drug contract development, has expanded its capabilities to include both a 17- and 34-cubic foot V-shell blender. This larger scale clinical manufacturing and support equipment will allow for a smooth transition from formulation development through clinical trials and into small commercial launches.
CoreRx Named to Tampa’s 2011 Fast 50
CoreRx, fast becoming a world-recognized leader in early drug contract development, was announced today as one of Tampa Bay’s Fast 50 companies. The Tampa Bay Business Journal’s Fast 50 is a list of the fastest growing privately held companies in Tampa Bay over a span of three years. Last year, CoreRx was recognized as the 6th fastest growing company in the Tampa Bay region.
